ESMO 2018 Congress: Highlights in HR positive, HER2 negative advanced breast cancer LBA2 PR

Dr. Massimo Cristofanilli reports on key results from ESMO 2018 Congress: LBA2PR: Overall survival with palbociclib plus fulvestrant in women with hormone receptorpositive, human epidermal growth factor receptor 2negative advanced breast cancer: Analyses from PALOMA3. Produced by the European Society for Medical Oncology